Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.

Visaria, Jay; Uzoigwe, Chioma; Swift, Caroline; Dang-Tan, Tam; Paprocki, Yurek; Willey, Vincent J

Visaria, Jay; Uzoigwe, Chioma; Swift, Caroline; Dang-Tan, Tam; Paprocki, Yurek; Willey, Vincent J.

Afiliación

Visaria J; HealthCore Inc, Wilmington, Delaware.
Uzoigwe C; Novo Nordisk Inc, Plainsboro Township, New Jersey.
Swift C; Novo Nordisk Inc, Plainsboro Township, New Jersey.
Dang-Tan T; Novo Nordisk Inc, Plainsboro Township, New Jersey.
Paprocki Y; Novo Nordisk Inc, Plainsboro Township, New Jersey.
Willey VJ; HealthCore Inc, Wilmington, Delaware. Electronic address: vwilley@healthcore.com.

Clin Ther ; 43(5): 808-821, 2021 05.

Article en En | MEDLINE | ID: mdl-33785221

Asunto(s)

Diabetes Mellitus Tipo 2; Medicare Part C; Anciano; Estudios de Cohortes; Diabetes Mellitus Tipo 2/tratamiento farmacológico; Receptor del Péptido 1 Similar al Glucagón; Péptidos Similares al Glucagón; Hemoglobina Glucada/análisis; Humanos; Hipoglucemiantes; Estudios Retrospectivos; Estados Unidos

Palabras clave

GLP-1RA; T2DM; glucose control; hemoglobin A(1c); real-world; semaglutide; type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Medicare Part C / Diabetes Mellitus Tipo 2 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans País/Región como asunto: America do norte Idioma: En Revista: Clin Ther Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google